Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experience-Reference-Cited by-同舟云学术

Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experience

Published:2024-03-15 Issue:10 Volume:46 Page:2496-2507
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Russell Marika¹²^ORCID,Gild Matti L.³⁴⁵,Wirth Lori J.⁶,Robinson Bruce³⁴⁵,Karcioglu Amanda Silver¹²⁷⁸⁹,Iwata Ayaka¹²¹⁰,Athni Tejas S.¹¹,Abdelhamid Ahmed Amr H.¹²^ORCID,Randolph Gregory W.¹²¹²

Affiliation:

1. Division of Thyroid and Parathyroid Endocrine Surgery Harvard Medical School Boston Massachusetts USA

2. Department of Otolaryngology‐Head and Neck Surgery, Massachusetts Eye and Ear Infirmary Harvard Medical School Boston Massachusetts USA

3. Department of Endocrinology and Diabetes Royal North Shore Hospital Sydney Australia

4. Cancer Genetics Laboratory Kolling Institute of Medical Research Sydney Australia

5. Faculty of Medicine and Health University of Sydney Sydney Australia

6. Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA

7. Division of Otolaryngology‐Head and Neck Surgery North Shore University HealthSystem Evanston Illinois USA

8. Department of Surgery North Shore University HealthSystem Evanston Illinois USA

9. The University of Chicago Pritzker School of Medicine Chicago Illinois USA

10. Department of Otolaryngology‐Head and Neck Surgery Kaiser Permanente Santa Clara Medical Center Santa Clara California USA

11. Harvard Medical School Boston Massachusetts USA

12. Department of Surgery Massachusetts General Hospital, Harvard Medical School Boston Massachusetts USA

Abstract

AbstractBackgroundExperience with targeted neoadjuvant treatment for locoregionally advanced thyroid cancer is nascent.MethodsMulticenter retrospective case series examining targeted neoadjuvant treatment for locoregionally advanced thyroid cancer. The primary outcome was change in surgical morbidity as measured by two metrics developed for use in clinical trials to characterize surgical complexity and morbidity. Secondary outcomes included percentage of patients proceeding to surgery and percentage receiving an R0/R1 resection.ResultsSeventeen patients with varied molecular alterations, pathologies, and treatment regimens were included. Mean surgical complexity scores decreased between time points for baseline and postneoadjuvant treatment, postneoadjuvant treatment and surgery, and between baseline and surgery. Eleven patients (64.7%) underwent surgical resection, with 10 (58.8%) receiving an R0/R1 resection.ConclusionsNeoadjuvant treatment of advanced thyroid cancer improves resectability and decreases the morbidity of required surgical procedures. However, treatment is not uniformly effective.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27735

Reference29 articles.

1. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib inBRAFV600E-Mutated Anaplastic Thyroid Carcinoma

2. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series

3. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

4. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial

5. Aerodigestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial;Journal of the Endocrine Society;2024-07-12